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Introduction
Shortly after the introduction of laparoscopic video-assisted techniques 
there was a real revival of thoracoscopic procedures and the term 
VATS, video-assisted thoracic surgery, was introduced. VATS is pres-
ently used for a variety of thoracic diseases including lung cancer (1). 
However, it should be noted that VATS is merely a new approach and 
not an operation on itself. The present role of VATS for staging of lung 
cancer is discussed.
Advantages and disadvantages of VATS
As for laparoscopy, VATS implies the use of a video-monitor, thoraco-
scope and camera. Newly designed instruments, especially endostaplers, 
facilitate the procedure but have their own limitations, although ﬂexible 
instruments are presently commercially available. Most thoracic sur-
geons perform thoracoscopy with double lumen endotracheal intubation 
and single-lung ventilation, so CO2 insufﬂation is not required. 
Theoretical advantages of VATS include the use of small incisions 
for insertion of the thoracoports, less muscle destruction and no rib 
retraction. For this reason postoperative pain is probably reduced and 
hospital stay shorter which may give rise to an overall reduced cost. 
Disadvantages of VATS are less exposure, the presence of the ribs hin-
ders the manipulation of the instruments in contrast to laparoscopy, and 
the limitations of the monitor and instruments can give rise to a less 
adequate operation. Complete digital palpation of the lung parenchyma 
is not possible with VATS, which is a severe restriction in identifying, 
palpating and determining the size and extent of lung nodules. Patients 
must tolerate single-lung ventilation, dense adhesions between visceral 
and parietal pleura render thoracoscopy impossible, the equipment is 
expensive and long-term results are not fully known yet (2). The recent 
introduction of robotic systems with three dimensional visualisation 
and highly ﬂexible robotic arms creates new exciting possibilities to 
perform even complex thoracic procedures (3). 
VATS and staging of lung cancer
For invasive staging of non-small cell lung cancer (NSCLC) cervical, 
anterior, extended mediastinoscopy and VATS are used, each having its 
speciﬁc indications (4,5). 
Lymph nodes accessible by VATS include the right paratracheal and 
tracheobronchial lymph node stations, the left-sided para-aortic and 
aortopulmonary nodes, the posterior subcarinal, inferior mediasti-
nal and hilar lymph nodes (6,7). So, VATS is an adjunct to cervical 
mediastinoscopy and can replace an anterior mediastinoscopy but not 
a cervical one. In case of inconclusive ﬁndings on clinical staging 
video-assisted mediastinoscopy and thoracoscopy can be combined to 
improve accuracy (8). 
VATS has speciﬁc advantages. A more complete exploration of the ip-
silateral hemithorax is possible including a thorough investigation of a 
pleural effusion. Biopsies can be taken of presumed metastases and sat-
ellite nodules as well as suspicious contralateral lesions can be removed 
with endostaplers. For more difﬁcult lesions the insertion of a guide-
wire under CT guidance may be helpful. Resectability of the primary 
tumor can be determined, especially in case of possible mediastinal 
invasion (clinical T4). When there is suspected proximal vascular inva-
sion on multislice computed tomography, ﬂexible videopericardioscopy 
is technically feasible and allows a better assessment of T4 status (9).
Limitations of VATS are a longer operative time and the need for 
double lumen intubation. In case of dense pleural adhesions conversion 
to thoracotomy may be necessary (2). In contrast to cervical mediasti-
noscopy, thoracoscopic exploration is limited to one side only.
In a series of 40 patients with lymph nodes larger than 1.5 cm on CT 
scan, there were 30 cases of enlarged aortopulmonary nodes and 10 
periazygos or subcarinal nodes; 33 patients had lung cancer and in 14 
(42 %) a positive biopsy was obtained (10). In case of a negative frozen 
section examination, immediate resection was performed. Sensitivity 
and speciﬁcity of VATS in this series were 100 %.
Asamura et al. reported a series of 116 surgical candidates with docu-
mented or suspected lung cancer who underwent exploration and stag-
ing by VATS (11). In 5 patients (4.3 %) inoperable factors were found 
due to malignant pleural effusion or pleural dissemination. In 2 patients 
N2 nodal metastases were found in the aortopulmonary window and 
these patients were entered into a clinical trial (11). VATS was found 
useful for better selection of patients and evaluation of eligibility crite-
ria for prospective clinical trials. 
De Giacomo et al. reported 43 patients with clinically suspected stage 
IIIB disease who underwent VATS staging before neoadjuvant therapy 
(12). Patients were divided in 3 groups. Group I had a cytologically 
negative pleural effusion, group II CT suspicion of mediastinal inﬁltra-
tion (T4 disease) and group III presumed contralateral lymph nodes 
(N3 disease). In group I 60 % of patients had indeed stage IIIB disease, 
in group II 50 % had histologically proven T4 tumors and the 3 patients 
with possible contralateral lymph nodes had N3 disease. In this series 
VATS provided a correct staging in 91 % of patients (12).
In a series of 105 consecutive patients with NSCLC who underwent 
thoracoscopic staging, VATS was accurate for evaluation of T3, T4 and 
T doubtful clinical disease (13). In contrast, overall diagnostic accuracy 
of thoracoscopy for clinical N2 disease was only 63%.
VATS and restaging of lung cancer
Although the data are limited, VATS is also useful for restaging of 
proven IIIA-N2 disease after induction therapy. In CALBG 39803 
study 70 patients from 10 institutions underwent VATS restaging of N2 
involvement after induction chemo- and/or radiotherapy (14). In 24% 
of cases VATS was unsuccessful due to adhesions, tumor bulk, airway 
injury or inadequate lung deﬂation. Sensitivity, speciﬁcity and negative 
predictive value of VATS were 75, 100 and 75.8%, respectively. 
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Introduction
For patients with lung cancer preoperative evaluation of the mediastinal 
lymph nodes is important to estimate local operabiliy or/and to consider 
the necessity of neoadjuvant treatment. Cervical mediastinoscopy (CM) 
is generally accepted as a safe and highly accurate procedure in the 
staging of lung cancer. Nodes accessible to CM are the levels of supe-
rior (level 2R and 2L) and inferior (level 4R and 4L) paratracheal and 
subcarinal (level 7) nodal stations. Aditionally extended CM and left 
parasternal mediastinotomy allow the exploration of aortopulmonary 
window (level 5) and anterior mediastinal nodes (level 6). Until the be-
ginning of the nineties, repeat mediastinoscopy (RM) was considered to 
be contraindicated because of ﬁbrosis, due to prior exploration and the 
increased surgical risk to injure vital structures. Neoadjuvant clinical 
trials with induction chemotherapy or chemoradiation made necessary 
this agressive re-exploration of the upper mediastinum in order to select 
patients with a higher probability to undergo complete resection and 
reduce the number of explorative thoracotomies in patients with locally 
advanced lung cancer. These series included small number of patients, 
but demonstrated a technical feasibility and a high diagnostical accu-
racy. Further indications were reported in patients after insufﬁcient ﬁrst 
mediastinoscopy and in the assessment of recurrent or second primary 
lung neoplasms. 
The aim of this presentation is to represent the large experience of one 
institution with this method, specially the indications, the technical 
characteristics, the intra- and postoperative complications, at least the 
efﬁcacy of RM as a staging procedure in view of new methods like the 
positron emission tomography (FDG-PET and FDG-PET/CT) and the 
endobronchial (EBUS) or endoscopic (EUS) ultrasound guided ﬁne-
needle aspiration (FNA). 
Material and methods
From 1968 to 2004 279 patients (66 females and 213 males with a 
mean age of 58 years, range, 28 to 78years) with lung cancer under-
went a re-do-mediastinoscopy, 12 because of inadequate ﬁrst procedure 
(group A), 67 because of recurrent (group B) and 35 of second primary 
lung cancer (group C), ﬁnally 165 after induction chemo-/radiotherapy 
for IIIa and IIIb disease (group D). Before induction 116 patients 
had a N2 and 49 a N3-disease. Neoadjuvant treatment included 3 
courses chemotherapy (three cycles of split-dose cisplatin 60mg/m2 
days 1,7 and etoposide 150mg/m2 days 3,4,5) followed by concurrent 
chemoradiotherapy(one cycle cisplatin 50mg/m2 days 2,9 and etoposide 
100mg/m2 days 4,5,6 combined with 45 Gy hyperfractionated acceler-
ated radiotherapy to primary tumor and mediastinal nodes). Restaging 
was performed by means of CT scan of the chest and upper abdomen, 
CT of the brain, bone scan and bronchoscopy. Patients with radiologi-
cal evidence of tumor remission or stable disease and Karnowsky 
index of more than 70% underwent RM. The interval between ﬁrst and 
second procedure were in group A 17 days (range, 12 to 38), in group B 
14 months (5 to 29 months) in group C 27 months (19-124 months) and 
in group D 132 days (113-145). RM was performed with resection of 
the scar of the ﬁrst operation and preparation to the pretracheal fascia. 
Digital maneuver or/and sharp preparation followed with determina-
tion and removal of adhesions along the „mediastiniscopy route”. After 
inserting the mediastinoscope we tried to obtain biopsies from the same 
nodal stations as by the ﬁrst mediastinoscopy. Sometimes is technicaly 
easer to insert the mediastinoscope through the left side of the trachea, 
because the careful preservation of the recurrens nerve by the initial 
mediastinoscopy resulted to less nodal biopsies and less adhesions. All 
accessible lymph nodes were sampled and mapped according to the 
revised regional lymph node classiﬁcation for lung cancer by Moun-
tain. A RM was considered as complete if bilateral inferior paratracheal 
(level 4R and 4L) and subcarinal (level 7) nodal stations were reached.
Results
Non intra- or postoperative deaths was observed, the loss of blood dur-
ing the procedure amounted on an average of 26 ml (range 10 to 160 
ml) and was not different to the ﬁrst operation. Three patients devel-
oped postoperative a recurrens nerve palsy, two a wound infection and 
two a cardiac arrhytmia. Because of the presence of diffuse inseparable 
adhesions. RM was not possible in 5 and incomplete in 14 cases (1.8% 
and 5.2% respectively). RM proved a N2 or N3 disease in 3/12 cases 
of group A (25%), in 17/67 of group B (25.4%) and in 6/35 of group C 
(17.1%). In the group D 116 patients had N2 and 49 N3 disease before 
induction treatment. The most frequent histological type found was 
squamous cell carcinoma (59p.) followed by adenocarcinoma (55p.), 
large cell carcinoma (19p.), small cell carcinoma (28p.) and mixed type 
of lung cancer in 4 cases. During the 160 RM biopsies was taken by a 
total of 528 lymph node stations (mean, 3.3). 
Comment
46 years after its introduction by Carlens in 1959, CM continues to be 
an important step in evaluation of the mediastinal lymph node status 
and in selection of patients with lung cancer before surgery. RM were 
rare and the number of demonstrated cases very limited, so that any 
analysis of these data were doubtful and questioned. Furthermore RM 
considered to be as a difﬁcult and complex operation because of the 
presense of peritracheal adhesions particularly between the trachea and 
the innominate artery. Meersschaut et al. reported ﬁrst about a large 
series of 140 RM as a routine staging procedure without deaths due to 
the procedure and without complications necessitating surgical inter-
vention. RM has been performed for different indications: in patients 
with incomplete ﬁrst mediastinoscopy, assessment of recurrent tumors, 
assessment of second primary tumors and in patients after neoadjuvant 
chemotherapy. Mediastinoscopy has been also compared with other 
diagnostical examinations, particularly with imaging techniques as 
computed tomography and magnetic resonance. CT scan and MRI are 
unable to distinguish hyperplastic, antracotic, granulomatous nodes 
or ﬁbrotic tissue after induction treatment from malignant nodes. The 
